Literature DB >> 29788045

Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance.

Patricia Escandón1, Nancy A Chow2, Diego H Caceres2, Lalitha Gade2, Elizabeth L Berkow2, Paige Armstrong2, Sandra Rivera1, Elizabeth Misas3,4, Carolina Duarte1, Heather Moulton-Meissner5, Rory M Welsh2, Claudia Parra6, Luz Angela Pescador7, Nohora Villalobos8, Soraya Salcedo9, Indira Berrio10,11, Carmen Varón12, Andrés Espinosa-Bode13, Shawn R Lockhart2, Brendan R Jackson2, Anastasia P Litvintseva2, Mauricio Beltran1, Tom M Chiller2.   

Abstract

Background: Candida auris is a multidrug-resistant yeast associated with hospital outbreaks worldwide. During 2015-2016, multiple outbreaks were reported in Colombia. We aimed to understand the extent of contamination in healthcare settings and to characterize the molecular epidemiology of C. auris in Colombia.
Methods: We sampled patients, patient contacts, healthcare workers, and the environment in 4 hospitals with recent C. auris outbreaks. Using standardized protocols, people were swabbed at different body sites. Patient and procedure rooms were sectioned into 4 zones and surfaces were swabbed. We performed whole-genome sequencing (WGS) and antifungal susceptibility testing (AFST) on all isolates.
Results: Seven of the 17 (41%) people swabbed were found to be colonized. Candida auris was isolated from 37 of 322 (11%) environmental samples. These were collected from a variety of items in all 4 zones. WGS and AFST revealed that although isolates were similar throughout the country, isolates from the northern region were genetically distinct and more resistant to amphotericin B (AmB) than the isolates from central Colombia. Four novel nonsynonymous mutations were found to be significantly associated with AmB resistance. Conclusions: Our results show that extensive C. auris contamination can occur and highlight the importance of adherence to appropriate infection control practices and disinfection strategies. Observed genetic diversity supports healthcare transmission and a recent expansion of C. auris within Colombia with divergent AmB susceptibility.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29788045     DOI: 10.1093/cid/ciy411

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  52 in total

1.  Direct Detection of Emergent Fungal Pathogen Candida auris in Clinical Skin Swabs by SYBR Green-Based Quantitative PCR Assay.

Authors:  D Joseph Sexton; Milena Kordalewska; Meghan L Bentz; Rory M Welsh; David S Perlin; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

2.  In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen; Rasmus Krøger Hare; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  Novel ERG11 and TAC1b mutations associated with azole resistance in Candida auris.

Authors:  Jizhou Li; Alix T Coste; Maroussia Liechti; Daniel Bachmann; Dominique Sanglard; Frederic Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

4.  Candidemia in Colombia

Authors:  Jorge Alberto Cortés; José Franklin Ruiz; Lizeth Natalia Melgarejo-Moreno; Elkin V Lemos
Journal:  Biomedica       Date:  2020-03-01       Impact factor: 0.935

5.  The LUFS domain, its transcriptional regulator proteins, and drug resistance in the fungal pathogen Candida auris.

Authors:  Elizabeth Misas; Patricia Escandón; Juan G McEwen; Oliver K Clay
Journal:  Protein Sci       Date:  2019-11       Impact factor: 6.725

6.  Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program.

Authors:  Michael A Pfaller; Shawn A Messer; Lalitagauri M Deshpande; Paul R Rhomberg; Eric A Utt; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 7.  Candida auris: A Quick Review on Identification, Current Treatments, and Challenges.

Authors:  Lucia Černáková; Maryam Roudbary; Susana Brás; Silva Tafaj; Célia F Rodrigues
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

8.  In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa.

Authors:  Tsidiso G Maphanga; Serisha D Naicker; Stanford Kwenda; Jose F Muñoz; Erika van Schalkwyk; Jeannette Wadula; Trusha Nana; Arshad Ismail; Jennifer Coetzee; Chetna Govind; Phillip S Mtshali; Ruth S Mpembe; Nelesh P Govender
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

9.  Clade distribution of Candida auris in South Africa using whole genome sequencing of clinical and environmental isolates.

Authors:  Serisha D Naicker; Tsidiso G Maphanga; Nancy A Chow; Mushal Allam; Stanford Kwenda; Arshad Ismail; Nelesh P Govender
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

10.  Candida auris infection and biofilm formation: going beyond the surface.

Authors:  Mark V Horton; Jeniel E Nett
Journal:  Curr Clin Microbiol Rep       Date:  2020-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.